GT Biopharma (FRA:OXIA) Cyclically Adjusted FCF per Share: €-2,149.36 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OXIA GT Biopharma Inc FRA:OXIA
28 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Cyclically Adjusted FCF per Share?

GT Biopharma FRA:OXIA 28 Cyclically Adjusted FCF per Share is €-2,149.36 as of Mar. 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GT Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.071. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2,149.36 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -5.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -63.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GT Biopharma was 21.80% per year. The lowest was -534.70% per year. And the median was -2.30% per year.

As of today (2026-07-18), GT Biopharma's current stock price is €4.77. GT Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2,149.36. GT Biopharma's Cyclically Adjusted Price-to-FCF of today is .


GT Biopharma  (FRA:OXIA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GT Biopharma Cyclically Adjusted FCF per Share Related Terms


GT Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Cyclically Adjusted FCF per Share Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -137.20 -165.68 -149.46 -274.78 -1,096.27

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -394.98 -239.31 -1,471.34 -1,096.27 -2,149.36

FRA:OXIA vs INTI, HIND, TPST: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, GT Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:OXIA
28GF Score
GT Biopharma Inc FRA:OXIA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GT Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.071/330.2130*330.2130
=-0.071

Current CPI (Mar. 2026) = 330.2130.

GT Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.381 241.018 -0.522
201609 -0.202 241.428 -0.276
201612 -0.052 241.432 -0.071
201703 -608.000 243.801 -823.497
201706 -348.000 244.955 -469.123
201709 -60.548 246.819 -81.006
201712 -18.551 246.524 -24.849
201803 -34.990 249.554 -46.299
201806 -15.500 251.989 -20.312
201809 -30.041 252.439 -39.296
201812 -11.323 251.233 -14.883
201903 -8.500 254.202 -11.042
201906 -9.431 256.143 -12.158
201909 -8.887 256.759 -11.429
201912 -3.190 256.974 -4.099
202003 -1.474 258.115 -1.886
202006 -21.482 257.797 -27.516
202009 -9.627 260.280 -12.214
202012 -9.103 260.474 -11.540
202103 -5.721 264.877 -7.132
202106 -3.186 271.696 -3.872
202109 -3.193 274.310 -3.844
202112 -2.827 278.802 -3.348
202203 -4.372 287.504 -5.021
202206 -2.532 296.311 -2.822
202209 -2.817 296.808 -3.134
202212 -3.622 296.797 -4.030
202303 -2.506 301.836 -2.742
202306 -1.334 305.109 -1.444
202309 -1.346 307.789 -1.444
202312 -1.359 306.746 -1.463
202403 -2.773 312.332 -2.932
202406 -1.919 314.175 -2.017
202409 -1.104 315.301 -1.156
202412 -1.044 315.605 -1.092
202503 -0.869 319.799 -0.897
202506 -0.943 322.561 -0.965
202509 -0.795 324.800 -0.808
202512 -0.134 324.054 -0.137
202603 -0.071 330.213 -0.071

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2,149.36 mean?
GT Biopharma (FRA:OXIA) has a Cyclically Adjusted FCF per Share of €-2,149.36 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's Cyclically Adjusted FCF per Share too high?
GT Biopharma's current Cyclically Adjusted FCF per Share is €-2,149.36. Overall, GT Biopharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Cyclically Adjusted FCF per Share compare to INTI and HIND?
GT Biopharma's Cyclically Adjusted FCF per Share of €-2,149.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on GT Biopharma and its competitors. GT Biopharma's current Cyclically Adjusted FCF per Share is €-2,149.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current Cyclically Adjusted FCF per Share of €-2,149.36. The current Cyclically Adjusted FCF per Share is €-2,149.36. GT Biopharma's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current Cyclically Adjusted FCF per Share is €-2,149.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
28GF Score

Get the complete analysis for FRA:OXIA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price